ORIGINAL ARTICLE

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

Donald A Mahler,1,2 Anthony D’Urzo,3 Eric D Bateman,4 Serir A Özkan,5 Tracy White,6 Clare Peckitt,7 Cheryl Lassen,7 Benjamin Kramer,6 on behalf of the INTRUST-1 and INTRUST-2 study investigators

ABSTRACT

Current guidelines recommend treatment with one or more long-acting bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (COPD). The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β2 agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone.

Methods In two identical designed, double-blind, 12-week studies, patients with moderate to severe COPD were randomised to indacaterol 150 μg once daily or matching placebo. All patients concurrently received open-label tiotropium 18 μg once daily. The primary outcome was standardised area under the curve of forced expiratory volume in 1 s (FEV₁) from 5 min to 8 h post dose at week 12. The key secondary outcome was 24 h post-dose (‘trough’) FEV₁ at week 12. Resting inspiratory capacity (IC) was measured in a subgroup.

Results 1134 and 1142 patients were randomised in studies 1 and 2; 94% and 94% completed. Compared with monotherapy, concurrent therapy increased FEV₁ (area under the curve by 130 and 120 ml, trough by 80 and 70 ml; all p <0.001) and trough IC (by 130 and 100 ml, p <0.011). Cough was more common with indacaterol plus tiotropium (10% and 9%) than with tiotropium alone (4% and 4%). Most cases (~90%) of cough were mild. Other adverse events were similar for the treatment groups.

Conclusions Compared with tiotropium monotherapy, indacaterol plus tiotropium provided greater bronchodilation and lung deflation (reflected by increased resting IC). Adverse events were similar between treatments apart from mild cough being more common with indacaterol plus tiotropium. These results support COPD guideline recommendations to combine bronchodilators with different mechanisms of action.

Trial registration numbers NCT00846586 and NCT00877383.

INTRODUCTION

Current guidelines recommend treatment with one or more long-acting bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (COPD).1–5 The candidate agents include the long-acting muscarinic antagonist (LAMA) tiotropium, given once daily,4 5 and the long-acting β2 agonists (LABAs) formoterol and salmeterol, given twice daily, or the once-daily indacaterol. Given as bronchodilator monotherapy, indacaterol has been shown to be effective and to have a good safety profile in patients with moderate to severe COPD in placebo-controlled studies of up to 1 year in duration.5–9 Indacaterol has demonstrated superiority in bronchodilator efficacy and clinical outcomes compared with the twice daily LABAs,6–8 and was shown to perform at least as well as tiotropium.9–11

In general, the addition of a second bronchodilator from a different pharmacological class has
been shown to improve lung function, symptoms and health status compared with a single bronchodilator.\textsuperscript{12–18} However, much of the data supporting combination bronchodilator treatment involves short-term studies\textsuperscript{14–16} or the use of short-acting bronchodilators.\textsuperscript{12 13} There are limited data for the combination of once-daily bronchodilators.\textsuperscript{19} Van Noord and colleagues\textsuperscript{19} reported that a once-daily dual bronchodilator consisting of indacaterol and glycopyrronium provided greater bronchodilation compared with indacaterol monotherapy and placebo for 7 days in 135 patients with moderate to severe COPD.

In the present study, we report the results of two identically designed studies examining the efficacy of two once-daily inhaled bronchodilator medications, indacaterol and tiotropium. The hypothesis of the two studies was that the concurrent use of a once-daily LABA and a once-daily LAMA would provide greater bronchodilation and reduce hyperinflation compared with a LAMA alone. Duplicate studies were conducted to meet US regulatory requirements.

METHODS

Patients

Participating physicians enrolled patients aged ≥40 years with moderate to severe COPD (defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007 criteria\textsuperscript{20}), with a smoking history ≥10 pack-years and post-bronchodilator (salbutamol 100 µg × four puffs) forced expiratory volume in 1 s (FEV\textsubscript{1}) ≤65% and ≥30% of predicted normal, and post-bronchodilator FEV\textsubscript{1}/forced vital capacity <70% at screening. The midpoint of GOLD stage II, namely FEV\textsubscript{1} 65% of predicted, was chosen as the upper limit for the protocol of this study evaluating two long-acting bronchodilators to target a more ‘severe’ GOLD II patient population that would benefit from combined bronchodilator treatment. GOLD guidelines at that time stated that one or more long-acting bronchodilators should be used for patients in GOLD stage II, and we believe that in practice this would comprise initial treatment with a single bronchodilator with another long-acting bronchodilator being added as patients become more symptomatic. Patients were not eligible if they had a history of asthma or had experienced a respiratory tract infection or COPD exacerbation within the previous 6 weeks.

Study design

Two identically designed, randomised, double-blind, 12-week studies were conducted. Study 1 involved 186 centres in 14 countries: Argentina (10), Australia (6), Colombia (5), Denmark (5), Germany (25), Greece (4), Guatemala (5), Mexico (5), Peru (6), Philippines (2), South Africa (6), Spain (13), Turkey (13) and USA (81). Study 2 had 182 centres in 11 countries: Argentina (9), Canada (16), Colombia (3), Czech Republic (9), Hungary (4), India (9), Netherlands (6), Philippines (5), Slovakia (10), Spain (11) and USA (102). Data were collected from outpatient clinics and physicians’ offices.

Study treatments

Patients were randomised to treatment with indacaterol 150 µg once daily or placebo to indacaterol. All patients concurrently received tiotropium 18 µg once daily, and all treatments were taken once daily via their proprietary single-dose dry-powder inhalers. Study treatments were taken at the same time each morning and in the fixed order of tiotropium followed by indacaterol/placebo, to be taken as soon after each other as possible. Salbutamol (albuterol in the USA) was available for as-needed use.

Patients receiving inhaled corticosteroids (ICS) at baseline continued treatment (or were switched to ICS monotherapy if taken as a fixed combination with a bronchodilator) at equivalent dose and regimen during the study. Other COPD treatments were withdrawn with appropriate washouts prior to screening (short-acting β\textsubscript{2} agonists other than allowed in the study, 6 h; short-acting anticholinergics, 8 h; LABAs, 48 h; theophylline, 7 days).

Randomisation and blinding

Randomisation (1:1) was performed using an automated interactive voice response system and was stratified by COPD severity (moderate or severe), with balance maintained at country level. Patients and staff at participating centres were unaware of treatment assignment. The tiotropium in both arms was given open label, and blinding was achieved by the use of placebo to indacaterol (ie, placebo given via the inhaler used for indacaterol). Patients, investigators, those performing the assessments and data analysts were blinded unless an emergency arose for a patient.

Objectives, assessments and outcome measures

The primary objective was to demonstrate superiority of indacaterol plus tiotropium versus tiotropium plus placebo in its effect on standardised area under the curve (AUC) of FEV\textsubscript{1}, from 5 min to 8 h post dose (FEV\textsubscript{1} AUC\textsubscript{5min–8h}) after 12 weeks (primary variable). The key secondary variable was 24 h post-dose FEV\textsubscript{1} (‘trough’; mean of measurements made at 25 h 10 min and 25 h 45 min post dose) at week 12. Further efficacy variables included other spirometric values (FEV\textsubscript{1} at other times and forced vital capacity). Exploratory variables were inspiratory capacity (IC, measured in a subgroup of approximately 120 patients per treatment arm) and use of as-needed salbutamol and symptoms. The patients in whom IC was measured were from study centres that elected to perform this measurement. Patients used diaries to record the number of salbutamol puffs used and severity of cough, wheeze, breathlessness and sputum production and colour during the last 12 h on four-point scales of increasing severity, each morning (premedication) and evening; there is no established threshold of clinical significance for these measures.

Safety data included adverse events, notable vital signs (pulse, blood pressure), blood chemistry (blood glucose, serum potassium) and ECG (QTc interval, corrected using Fridericia’s formula) at any time post baseline (measured pre dose and 30 min post dose at weeks 4, 8 and 12).

Statistical methods

Two populations were defined for analysis. The full analysis (intention-to-treat) population comprised randomised patients who received at least one dose of the study drug, analysed according to allocated treatment group. The safety population comprised patients who received at least one dose of the study drug, analysed according to treatment received.

The primary variable (FEV\textsubscript{1} AUC\textsubscript{5min–8h} after 12 weeks) was analysed using a mixed-model analysis of covariance containing treatment as a fixed effect and, as covariates, baseline FEV\textsubscript{1} and FEV\textsubscript{1} before and after salbutamol and before and after ipratropium inhalation. The model also included disease severity (moderate/severe), country, smoking history and ICS use as fixed effects and centre nested within country as a random effect. Similar methods were used to analyse secondary efficacy variables, with appropriate baseline measurements as covariates.
To allow for multiplicity, a hierarchical testing procedure was used to maintain an $\alpha$ level of 0.05 for the primary and key secondary variables (FEV$_1$ AUC$_{5\text{min}-8\text{h}}$ and trough FEV$_1$ after 12 weeks). Any missing values were carried forward from the latest available of the values at weeks 4 or 8 (‘last observation carried forward’). Exploratory analyses of FEV$_1$ AUC$_{5\text{min}-8\text{h}}$ at week 12 were performed in patient subgroups according to disease severity (moderate or less, severe or worse), smoking history (current smoker, ex-smoker) and the use of ICS at baseline (yes, no), using appropriate interaction terms and covariates.

Results are shown as least squares means with SEs for group mean values and 95% CIs for differences between treatments. Adverse events and other safety data are summarised descriptively.

For the primary analysis, to show superiority in standardised FEV$_1$ AUC$_{5\text{min}-8\text{h}}$ by 60 ml$^{17}$ with a SD of 220 ml, 478 evaluable patients per arm were needed for 98% power which, with an assumed dropout of 15%, required 565 patients per arm or a total of 1126. For the key secondary analysis of trough FEV$_1$, assuming a difference of 45 ml$^{14}$ and a SD of 225 ml, 478 evaluable patients per arm would provide 87% power. Since the key secondary variable would only be tested if the primary objective was significant, the power for the key secondary would be 85% (ie, 87% × 98%).

**RESULTS**

The studies were conducted between March 2009 and March 2010.

**Patients**

Patient disposition is shown in figure 1. The main reason for screening failure was not meeting diagnostic/severity criteria, followed by unacceptable test procedure results and withdrawal of consent. Completion rates were similar between treatment groups and studies: 93% and 94% of patients in study 1, and 95% and 94% in study 2. Patient demographics and other baseline characteristics were similar between the two treatment groups, apart from a slightly higher proportion of baseline ICS users in the indacaterol plus tiotropium treatment group of study 2. The two studies were well balanced, apart from a higher proportion of Asian patients in study 2 (table 1).

**Lung function**

In both studies the primary objective was met, and superiority of indacaterol plus tiotropium versus tiotropium plus placebo was demonstrated for FEV$_1$ AUC$_{5\text{min}-8\text{h}}$ at week 12, with differences of 180 ml (95% CI 160 to 190) and 120 ml (95% CI 90 to 140) in studies 1 and 2, respectively (both $p<0.001$). Results for FEV$_1$ AUC$_{5\text{min}-8\text{h}}$ in the subgroups analysed according to COPD severity, smoking status and ICS use are shown in table 2.
Differences between indacaterol plus tiotropium and tiotropium plus placebo remained statistically significant in all subgroups, although the differences within each pair of subgroups were wider in study 2 than in study 1, particularly for smokers versus ex-smokers.

Indacaterol plus tiotropium also performed better than tiotropium plus placebo for the key secondary variable, trough FEV1 (last observation carried forward) at week 12, with differences of 80 ml (95% CI 50 to 100) and 70 ml (95% CI 50 to 78) (both p<0.001). Again, statistically significant differences between the two treatments were maintained in subgroups analysed according to COPD severity, smoking status and ICS use (table 2).

After the first dose on day 1 of treatment, indacaterol plus tiotropium had a significantly greater effect than tiotropium plus placebo on FEV1 at 5 min post dose, with differences of 90 ml (95% CI 80 to 100 ml) and 80 ml (95% CI 70 to 90 ml) (both p<0.001). At this time point, least square mean increases

### Table 1 Demographics and baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Study 1</th>
<th></th>
<th>Study 2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indacaterol + tiotropium (n=570)</td>
<td>Tiotropium + placebo (n=561)</td>
<td>Indacaterol + tiotropium (n=572)</td>
<td>Tiotropium + placebo (n=570)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>64.0 (8.07)</td>
<td>63.4 (9.22)</td>
<td>63.1 (8.83)</td>
<td>62.8 (8.98)</td>
</tr>
<tr>
<td>Sex, men/women, %</td>
<td>70/30</td>
<td>67/33</td>
<td>63/37</td>
<td>68/32</td>
</tr>
<tr>
<td>Race, %</td>
<td>78.2</td>
<td>78.6</td>
<td>77.8</td>
<td>79.3</td>
</tr>
<tr>
<td>Caucasian</td>
<td>0.4</td>
<td>1.2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Native American</td>
<td>14.9</td>
<td>14.4</td>
<td>2.6</td>
<td>2.3</td>
</tr>
<tr>
<td>Duration of COPD (years), mean (SD)</td>
<td>7.1 (6.12)</td>
<td>6.6 (6.45)</td>
<td>7.3 (6.48)</td>
<td>7.1 (6.26)</td>
</tr>
<tr>
<td>Severity of COPD, n (%)*</td>
<td>Moderate†</td>
<td>47</td>
<td>47</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Severe or very severe</td>
<td>53</td>
<td>53</td>
<td>54</td>
</tr>
<tr>
<td>ICS use, yes/no %</td>
<td>52/48</td>
<td>52/48</td>
<td>57/43</td>
<td>51/49</td>
</tr>
<tr>
<td>Ex-smoker/smoker, %</td>
<td>60/40</td>
<td>64/36</td>
<td>62/38</td>
<td>57/43</td>
</tr>
<tr>
<td>Pack-years, mean (SD)</td>
<td>47.2 (25.36)</td>
<td>47.2 (26.58)</td>
<td>46.1 (25.52)</td>
<td>46.3 (24.64)</td>
</tr>
<tr>
<td>FEV1, litres (post salbutamol)</td>
<td>1.16 (0.367)</td>
<td>1.17 (0.396)</td>
<td>1.16 (0.373)</td>
<td>1.18 (0.373)</td>
</tr>
<tr>
<td>FEV1/FVC (post salbutamol)</td>
<td>46.4 (9.74)</td>
<td>45.8 (10.00)</td>
<td>47.0 (10.21)</td>
<td>47.2 (9.53)</td>
</tr>
<tr>
<td>FEV1, litres (pre ipratropium), mean (SD)</td>
<td>1.15 (0.357)</td>
<td>1.15 (0.384)</td>
<td>1.14 (0.364)</td>
<td>1.15 (0.356)</td>
</tr>
<tr>
<td>FEV1% predicted (pre salbutamol)</td>
<td>1.32 (0.367)</td>
<td>1.33 (0.418)</td>
<td>1.29 (0.368)</td>
<td>1.32 (0.374)</td>
</tr>
<tr>
<td>FEV1 reversibility †</td>
<td>16.5 (14.48)</td>
<td>17.3 (17.13)</td>
<td>16.3 (15.85)</td>
<td>16.5 (16.27)</td>
</tr>
<tr>
<td>FEV1 reversibility †</td>
<td>16.5 (14.48)</td>
<td>17.3 (17.13)</td>
<td>16.3 (15.85)</td>
<td>16.5 (16.27)</td>
</tr>
<tr>
<td>FEV1 reversibility †</td>
<td>16.5 (14.48)</td>
<td>17.3 (17.13)</td>
<td>16.3 (15.85)</td>
<td>16.5 (16.27)</td>
</tr>
<tr>
<td>FEV1 reversibility †</td>
<td>16.5 (14.48)</td>
<td>17.3 (17.13)</td>
<td>16.3 (15.85)</td>
<td>16.5 (16.27)</td>
</tr>
</tbody>
</table>

*Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Data missing for one patient in study 2.
†Includes one patient (study 1, tiotropium group) with mild severity.
‡At screening, spirometry measurements were taken to assess bronchodilator reversibility, first to a short-acting β2 agonist (FEV1 measured 10–15 min after inhalation of 4×100 μg puffs of salbutamol (equivalent to 4×90 μg albuterol ex-mouthpiece) compared with pre-bronchodilator value) and, on the next morning, to an anticholinergic (FEV1 increase 1 h after inhalation of 2×21 μg ipratropium bromide (equivalent to 2×17 μg ipratropium ex-mouthpiece) compared with pre-bronchodilator value).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid.

### Table 2 Differences between treatments (indacaterol plus tiotropium—tiotropium plus placebo) in FEV1 AUC8h, and trough FEV1 in patient subgroups analysed according to COPD severity, smoking status and ICS use*

<table>
<thead>
<tr>
<th></th>
<th>Study 1</th>
<th></th>
<th>Study 2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indacaterol + tiotropium</td>
<td>Tiotropium + placebo</td>
<td>Indacaterol + tiotropium</td>
<td>Tiotropium + placebo</td>
</tr>
<tr>
<td>FEV1 AUC8h</td>
<td>120 ml (90 to 160) (n=233/237)§</td>
<td>130 ml (90 to 160) (n=247/237)</td>
<td>90 ml (50 to 130) (n=258/260)</td>
<td>90 ml (60 to 120) (n=261/258)</td>
</tr>
<tr>
<td></td>
<td>130 ml (100 to 160) (n=272/267)</td>
<td>110 ml (80 to 140) (n=283/267)</td>
<td>70 ml (30 to 110) (n=302/289)</td>
<td>60 ml (30 to 90) (n=304/306)</td>
</tr>
<tr>
<td>Smoker status</td>
<td>Ex-smoker</td>
<td>120 ml (90 to 150) (n=300/324)</td>
<td>140 ml (110 to 170) (n=331/285)</td>
<td>70 ml (40 to 110) (n=335/350)</td>
</tr>
<tr>
<td></td>
<td>Current smoker</td>
<td>130 ml (90 to 170) (n=205/180)</td>
<td>90 ml (50 to 120) (n=199/219)</td>
<td>80 ml (40 to 130) (n=228/199)</td>
</tr>
<tr>
<td>ICS use</td>
<td>No users</td>
<td>120 ml (90 to 180) (n=242/236)</td>
<td>140 ml (100 to 170) (n=229/251)</td>
<td>70 ml (30 to 110) (n=271/260)</td>
</tr>
<tr>
<td></td>
<td>Users</td>
<td>130 ml (100 to 160) (n=263/268)</td>
<td>100 ml (70 to 140) (n=301/253)</td>
<td>80 ml (50 to 120) (n=290/289)</td>
</tr>
</tbody>
</table>

Data are least squares means with 95% CI in parentheses. All treatment contrasts significant at p<0.001.
*The interaction term for treatment by subgroup was non-significant in all cases (p>0.1).
†Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007.
‡Includes one patient (study 1, tiotropium group) with mild severity.
§Patient numbers are for indacaterol + tiotropium and tiotropium groups, respectively.
AUC8h, area under the curve from 5 min to 8 h post dose; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid.


Downloaded from thorax.bmj.com on June 22, 2022 by guest. Protected by copyright.
from baseline in FEV₁ were 130 ml (95% CI 120 to 150) and 120 ml (95% CI 110 to 140) with indacaterol plus tiotropium treatment and 40 ml (95% CI 30 to 60) and 50 ml (95% CI 40 to 60) with tiotropium plus placebo. Indacaterol plus tiotropium was superior to tiotropium plus placebo for FEV₁ AUC<sub>5min–8h</sub> on day 1 (differences of 80 (95% CI 60 to 90) and 70 ml (95% CI 50 to 80), p<0.001) and for trough FEV₁ measured on day 2 (differences of 90 (95% CI 70 to 110) and 80 ml (95% CI 60 to 90), p<0.001).

Measurements of FEV₁ at individual time points after dosing at week 12 are shown in figure 2, with significant between-treatment differences at each time point (p<0.001). (Treatment contrasts for the trough measurements shown in the figure are without imputation for missing values.)

IC treatment contrasts at week 12 are shown in figure 3. The differences between indacaterol plus tiotropium and tiotropium plus placebo treatment were statistically significant at each time point, including trough (24 h post dose).

**Patient-reported symptoms and use of as-needed salbutamol**

Over the 12 weeks of the study, the decreases from baseline in COPD symptom scores and the use of as-needed salbutamol were statistically significantly greater in the combined treatment group in both studies (table 3).

**Safety**

Adverse events were reported for similar proportions of patients in the two treatment groups in both studies (table 4). Many of the most common events reflected the disease characteristics of COPD and had a similar incidence in all four treatment groups. The most common adverse event overall was COPD worsening. Cough was more common with the indacaterol plus tiotropium treatment. Most cases of cough with concurrent treatment were mild (54/59, 92%; and 46/52, 89%), and only one (moderate) case led to study drug discontinuation. Other differences between treatment groups (eg, in muscle spasms and dyspnoea) were small and not observed consistently in the two studies.

Two patients died during the treatment period in study 1, both in the indacaterol plus tiotropium treatment group (causes were anaphylaxis and myocardial infarction). Three patients died during the treatment period in study 2, one in the indacaterol plus tiotropium group (causes was myocardial infarction) and two in the tiotropium group (causes were unknown and cardiac arrest). Another two patients died in the 30 days following discontinuation of tiotropium (acute renal failure) or indacaterol plus tiotropium treatment (unknown cause). In the opinion of the investigators, apart from the death due to cardiac arrest (in the tiotropium group of study 2), all were considered unrelated to study treatment.

Serious adverse events were reported for similar proportions of patients in the indacaterol plus tiotropium and monotherapy groups: 3.7% and 3.0% (study 1) and 3.5% and 3.2% (study 2). The primary system organ classes in which 1% or more of patients had a serious adverse event were respiratory, thoracic and mediastinal disorders (1.1% and 1.6% with indacaterol plus tiotropium treatment; 2.1% and 1.6% with tiotropium), mostly comprising COPD worsening (1.1% and 1.6% with indacaterol plus tiotropium; 2.0% and 1.6% with tiotropium); and infections and infestations (1.1% and 1.2% with indacaterol plus tiotropium treatment; 0.5% and 0.7% with tiotropium), which included pneumonia and lower respiratory tract infections.

Results for vital signs, plasma potassium, blood glucose and QTc intervals are shown in table 5. Findings were generally similar between the two treatments; a numerically higher incidence of elevated systolic blood pressure with indacaterol plus tiotropium treatment in study 1 was not observed in study 2.

**DISCUSSION**

Several placebo-controlled studies have demonstrated the efficacy and safety of indacaterol given as long-acting bronchodilator monotherapy in patients with moderate to severe COPD. Its bronchodilator effect was shown to be superior to the twice-daily LABAs and at least as effective as tiotropium, although indacaterol had the faster onset of effect on first dose. Indacaterol was also shown to improve clinical outcomes (dyspnoea and health status) to a statistically significantly greater extent than tiotropium.

Coadministration of indacaterol and tiotropium provided significantly greater bronchodilation (AUC and trough FEV₁) compared with tiotropium alone. These differences were seen from the first dose onwards. The statistically significant differential bronchodilator effect was maintained in patient subgroups irrespective of baseline COPD severity, smoking status or ICS use. The differential between the two treatments was fairly constant between the subgroups in study 1 but...
differed somewhat in study 2, particularly in the smoking subgroups, where ex-smokers had a mean difference of 50 ml (advantage) over current smokers. Reasons for the difference are unknown but it could be due to the small sample size. Disease severity, smoking status and history were similar in the two studies, and the higher proportion of patients of Asian origin in study 2 (16.5% vs 5% in study 1, including 13.5% from India) did not influence treatment responsiveness (results not shown). The primary outcome was chosen to reflect the period of the day when patients are more active and when multiple spirometric assessments are more conveniently made. The results show an average increase in FEV₁ of 120–130 ml over this period with indacaterol plus tiotropium treatment versus tiotropium alone. The treatment differences from the analysis models in the two studies are compatible, with only small differences (of 10 ml) between studies. The average differences between the two treatments in their effect on trough FEV₁ may be regarded as similar

...indacaterol plus tiotropium treatment compared with tiotropium alone. Reasons for the difference are unknown but it could be due to the small sample size. Disease severity, smoking status and history were similar in the two subgroups, where ex-smokers had a mean difference of 50 ml (advantage) over current smokers. The results show an average increase in FEV₁ of 120–130 ml over this period with indacaterol plus tiotropium treatment versus tiotropium alone. The treatment differences from the analysis models in the two studies are compatible, with only small differences (of 10 ml) between studies. The average differences between the two treatments in their effect on trough FEV₁ may be regarded as similar.
plus tiotropium treatment was observed in both studies. This side effect has been observed with indacaterol in previous studies, and was not associated with any loss of efficacy or increased withdrawal from treatment.6–9 The overall safety of indacaterol has been previously demonstrated in other clinical studies, including 1 year of treatment with a 600 μg daily dose.9–21 Long-term clinical trials have shown that tiotropium has a good safety profile.5, 30–33

The enhanced efficacy of combining bronchodilator medications of different pharmacological classes has been recognised for many years, including the use of two short-acting agents1 2–3 as well as the combination of tiotropium with twice-daily β2 agonists.14–15 The putative mechanism for the additive effect of two different classes of once-daily bronchodilators as noted in our study could be the relaxation of bronchial smooth muscle secondary to independent effects on sympathetic and parasympathetic pathways. Alternative explanations may relate to differential distribution of β2-adrenergic and muscarinic receptors within the airways,24 or to an interaction between the two types of receptors, with potentiation of β2-receptor activation by muscarinic (M3) receptor blockade.16

There are several limitations of these two identical studies that demonstrate the efficacy and safety of indacaterol given concurrently with tiotropium. First, it would have been interesting to include indacaterol monotherapy as a third treatment arm. A direct comparison between indacaterol and tiotropium would provide important information for selecting initial long-acting bronchodilator therapy for patients with COPD.10 However, a placebo tiotropium capsule for use with its proprietary dry powder inhaler is not available for administration in a double-blind study. A second limitation is that more comprehensive clinical measures were not included as secondary outcomes in these studies. The treatment effects on dyspnea, health status and exacerbations are important clinical outcomes, and these measures should be included in subsequent clinical trials.35 Finally, the 150 μg indacaterol dose was used in the current studies. This was the lower of two doses submitted for approval at the time that the studies were designed and initiated. The 150 μg dose is currently approved in more than 50 countries, whereas 75 and 300 μg doses have also received regulatory approval in different countries. Randomised trials will be required to assess the effects of these lower and higher doses of indacaterol in combination with tiotropium.

Current guidelines1–3 state that combining bronchodilators with different mechanisms of action increases the magnitude of bronchodilation for equivalent or less side effects. These are the first 12-week studies to report on the efficacy of dual bronchodilation using two once-daily bronchodilators. The improvements in lung function with the combination of indacaterol and tiotropium confirm GOLD recommendations.1 Concurrent administration of indacaterol and tiotropium is an effective treatment strategy for patients with moderate to severe COPD to promote bronchodilation and lung deflation with no additional safety signal.

Acknowledgements Sarah Flice of CircleScience wrote the first draft of the manuscript and coordinated input from authors into subsequent drafts. This support was funded by Novartis. David Young of Novartis reviewed the manuscript. DATAMAP GmbH performed the statistical programming and analyses. David Lawrence of Novartis provided additional statistical support.

Contributors All authors had access to the study data, were involved in interpretation and/or presentation of the data for this report, reviewed and revised the initial draft and subsequent versions of the manuscript, had final responsibility for the decision to submit for publication and approved the version submitted.

Funding The study was funded by Novartis Pharma AG, the manufacturer of indacaterol. Novartis designed the study and analysed the data. Data were recorded at participating clinical centres and maintained by Novartis.

Competing interests DAM has received remuneration for participation in advisory boards and/or consulting from AstraZeneca, Boehringer-Ingelheim, DeepBreeze, Forest, GlaxoSmithKline, Merck, Nycomed, Novartis, and Sunovion. AD has received research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Novartis Canada/USA, Hoffmann-La Roche Limited, and KOS Pharmaceuticals. EDB has received remuneration for lectures, participation in advisory boards and/or consulting from Amgen, Almirall, AK Abello, Actelion, AstraZeneca, Boehringer Ingelheim, Elevation Pharma, Forest, GlaxoSmithKline, Merck, Nycomed, Novartis and Pfizer. SAO has received research grants from Novartis and Boehringer-Ingelheim. TW, CP, CL and BK are employees of Novartis, the study sponsor.

Patient consent Patients gave their written informed consent to participate before receiving any study treatment. Patients are not identifiable by the information given in the manuscript.

Ethics approval The study design was approved by independent ethics committees or review boards at each centre. Patients gave their written informed consent to participate before receiving any study treatment.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Chronic obstructive pulmonary disease


